WCN26-4723 LOW-DOSE DOTINURAD, A NOVEL URIC ACID-LOWERING AGENT THAT PROMOTES URIC ACID SECRETION, IS AN EFFECTIVE TREATMENT FOR MODERATE TO ADVANCED CHRONIC KIDNEY DISEASE

Read full text Summarise with VIRAT
Authors: Hiroshi Kanamori
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Accumulating evidences have suggested that hyperuricemia is associated with aggravation of chronic kidney disease (CKD). Treatment guidelines propose, the administration of a uric acid production inhibitor to achieve serum uric level below 6 mg / dL in CKD patients with hyperuricemia; however, the success rate is not satisfactory. Amidst this, the uric acid-lowering agent dotinurad was newly launched in 2020. This selectively inhibits URAT-1 in the proximal tubule, suppressing uric acid reabsorption.

Fields of Study & Subjects

Gout Hyperuricemia Uric Acid Chronic Kidney Disease and Diabetes Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104229–104229
Publication date
25 March 2026
Language
EN